Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Baseline Characteristics from Arise Study, an Italian Non-Interventional Study Assessing the Real-World Use of Acalabrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2024) 144 (Supplement 1): 7747.

https://doi.org/10.1182/blood-2024-199041

Published: 2024

Journal Articles

Survival after First Relapse in Marginal Zone Lymphomas: Prospective Data from the International Observational NF10 Study By the Fondazione Italiana Linfomi

Blood (2024) 144 (Supplement 1): 1639.

https://doi.org/10.1182/blood-2024-207886

Published: 2024

Journal Articles

Baseline Characteristics from CLL-ZANU2024, an Italian Non-Interventional Study Assessing the Real-World Use of Zanubrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Enrica Antonia Martino, Raffaella Pasquale, Isacco Ferrarini, Riccardo Moia, Andrea Visentin, Alessandro Sanna, Marina Motta, Massimo Moratti, Paolo Sportoletti, Annalisa Chiarenza, Alessandro Maggi, Valentina Zammit, Michele Merli, Idanna Innocenti, Claudia Giordano, Laura Nocilli, Massimiliano Postorino, Caterina Stelitano, Andrea Ferrario, Annamaria Frustaci, Stefania Scardino, Paola Anticoli Borza, Laura Ballotta, Salvatrice Mancuso, Gerardo Musuraca, Anna Mele, Sara Galimberti, Gioacchino Catania, Annamaria Giordano, Ilaria Angeletti, Luana Schiattone, Elsa Pennese, Rosanna Miccolis, Angelo Fama, Giulio Giordano, Catello Califano, Ernesto Vigna, Antonella Bruzzese, Giuliana Farina, Pietro Bulian, Giacomo Loseto, Barbara Pocali, Vanessa Innao, Piero Galieni, Vincenzo Ludovico Fraticelli, Candida Vitale, Azzurra Anna Romeo, Marco Rossi, Ilaria Scortechini, Federico Vozzella, Luigi Malandruccolo, Enrico Derenzini, Valentina di Martina, Roberto Marasca, Maria Ilaria Del Principe, Marta Coscia, Nicola Di Renzo, Luca Laurenti, Antonino Neri, Pellegrino Musto, Francesco Di Raimondo, Alessandra Tedeschi, Livio Trentin, Gianluca Gaidano, Fortunato Morabito, Valter Gattei, Massimo Gentile

Blood (2024) 144 (Supplement 1): 6794.

https://doi.org/10.1182/blood-2024-205354

Published: 2024

Journal Articles

Survival Patterns of Non-Randomized Patients in the IELSG37 Study: Deauville Score 4 Is Not Necessarily Associated with Poor Outcome in Primary Mediastinal Lymphoma

Emanuele Zucca, Luca Ceriani, Andrew S. Davies, Giovannino Ciccone, Umberto Ricardi, Alice Di Rocco, Iryna Kryachok, Barbara Botto, Monica Balzarotti, Alessandra Tucci, Vittorio Ruggero Zilioli, Sara Usai, Luca Arcaini, Elsa Pennese, Anna Dabrowska-Iwanicka, Andrés José María Ferreri, Franceso Merli, Wei Li Zhao, David Hodgson, Codruta Ionescu, Luigi Rigacci, Claudia Cellini, Caterina Stelitano, Stefano Volpetti, Carla Minoia, Michele Spina, Alexander Fossa, George Mikhaeel, Kate Cwynarski, Andrea Janikova, Yana Stepanishyna, Mats Jerkeman, Andreas Huettmann, Maria Gomes da Silva, Don A. Stevens, Sally F Barrington, Bogdan Małkowski, Ur Metser, Annibale Versari, Stephane Chauvie, Oreste Bagni, Kelly Cozens, Sonia Perticone, Nicoletta Ielmini, Letizia Deantonio, Jan Walewski, Marek Trneny, Mary Gospodarowicz, Franco Cavalli, Peter Johnson, Maurizio Martelli

Blood (2023) 142 (Supplement 1): 1718.

https://doi.org/10.1182/blood-2023-174093

Published: 2023

Journal Articles

A Snapshot of the Management of Chronic Lymphocytic Leukemia in Italy. Preliminary Analysis on over 3000 Patients Enrolled in the Gimema CLL2121 Trial

Blood (2023) 142 (Supplement 1): 6544.

https://doi.org/10.1182/blood-2023-188454

Published: 2023

Journal Articles

Real-World Outcome of Treatment with Single-Agent Ibrutinib in Patients with Chronic Lymphocytic Leukemia: Results from the Italian Study Evidence

Blood (2022) 140 (Supplement 1): 4178–4180.

https://doi.org/10.1182/blood-2022-166140

Published: 2022

Journal Articles

Obinutuzumab-Based Immunochemotherapy Mitigates Early Progression Risk with a Substantial 2-Year Progression-Free Survival (PFS) in Patients with Previously Untreated Advanced Follicular Lymphoma and a FLIPI Score ≥2: An Interim Analysis of the Ambispective Urban Study

Blood (2022) 140 (Supplement 1): 3638–3641.

https://doi.org/10.1182/blood-2022-165977

Published: 2022

Journal Articles

Comparison between R-COMP and R-CHOP in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Substudy of the Elderly Project By the Fondazione Italiana Linfomi

Blood (2021) 138 (Supplement 1): 2487.

https://doi.org/10.1182/blood-2021-150337

Published: 2021

Journal Articles

The Use of Ibrutinib in Italian CLL Patients Treated in a Real-World Setting (EVIDENCE): A Preliminary Report

Blood (2021) 138 (Supplement 1): 4684.

https://doi.org/10.1182/blood-2021-148378

Published: 2021

Journal Articles

Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs

Blood (2021) 137 (25): 3507–3517.

https://doi.org/10.1182/blood.2020008201

Published: 2021

Includes: Supplemental data

Journal Articles

Pre-Existing and Treatment-Emergent Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Drugs

Blood (2019) 134 (Supplement_1): 3044.

https://doi.org/10.1182/blood-2019-125530

Published: 2019

Journal Articles

Clinical Relevance of Individual Response to Iron Chelation Therapy (ICT) in Patients with Myelodysplastic Syndromes (MDS) and Transfusion Requirement

Blood (2019) 134 (Supplement_1): 3010.

https://doi.org/10.1182/blood-2019-129902

Published: 2019

Journal Articles

Definition and Validation of the New Elderly Prognostic Index (EPI) for Elderly Patients with Diffuse Large B-Cell Lymphoma Integrating Geriatric and Clinical Assessment: Results of the Prospective "Elderly Project" on 1353 Patients By the Fondazione Italiana Linfomi

Blood (2019) 134 (Supplement_1): 398.

https://doi.org/10.1182/blood-2019-123027

Published: 2019

Journal Articles

Unmanipulated, G-CSF-Primed Bone Marrow Transplantation From Haploidentical Donor for Patients with High-Risk Acute Myeloid Leukemia.

William Arcese, MD, Raffaella Cerretti, MD, Stella Santarone, MD, Gottardo De Angelis, MD, Pasqua Bavaro, MD, Manuela Testi, MD, Laura Cudillo, MD, Alessandra Picardi, MD, Elsa Pennese, MD, Gabriele Papalinetti, MD, Teresa Dentamaro, MD, Eleonora Ceresoli, MD, Benedetta Mariotti, MD, Fabio Di Piazza, Paolo Di Bartolomeo, MD

Blood (2012) 120 (21): 3122.

https://doi.org/10.1182/blood.V120.21.3122.3122

Published: 2012

Journal Articles

Cyclophosphamide, Vincristine, Myocet and Prednisone ± Rituximab (COMP±R) Regimen Is Safe and Effective as First Line or Salvage Therapy in Elderly Non Hodgkin Lymphoma (NHL): Preliminary Data of Single Centre Experience.

Elsa Pennese, MD, Claudio Cristofalo, MD, Michelina Dargenio, MD, Maria Rosaria De Paolis, MD, Pasquale Forese, MD, Rosella Matera, PhD, Giorgio Pugliese, MD, Giovanni Reddiconto, MD, Antonio Valacca, MD, Carolina Vergine, MD, Nicola Di Renzo, MD

Blood (2009) 114 (22): 3747.

https://doi.org/10.1182/blood.V114.22.3747.3747

Published: 2009

Journal Articles

Efficacy and Safety of Yttrium-90 Ibritumomab Tiuxetan in Older Patients with Indolent Non-Hodgkin Lymphoma.

Silvana Capalbo, Gaetano Palumbo, Matteo Dell'Olio, Maria Grazia Franzese, Attilio Guarini, Nicola Di Renzo, Giuseppina Spinosa, Angela Lapietra, Elsa Pennese V, Nicola Cascavilla, MD

Blood (2009) 114 (22): 4795.

https://doi.org/10.1182/blood.V114.22.4795.4795

Published: 2009

Journal Articles

Velcade, Thalidomide and Dexamethasone (VTD) Regimen Followed by High-Dose Chemotherapy Plus Autologous Stem Cell Transplant (HDT-ASCT) as Front-Line treatment in Newly Diagnosed Multiple Myeloma (MM) Patients: Preliminary Results of An ongoing Open Label Study

Nicola Di Renzo, Elsa Pennese, Pasquale Forese, Giovanni Reddiconto, Rosella Matera, Carolina Vergine, Antonia Falcone, Nicola Cascavilla

Blood (2008) 112 (11): 5203.

https://doi.org/10.1182/blood.V112.11.5203.5203

Published: 2008

Journal Articles

Incidence, Clinical Characteristics and Survival of Malignant Lymphomas in the Province of Modena (Italy); a Population-Based Study.

Stefano Luminari, Marina Cesaretti, Ivan Rashid, Elsa Pennese, Caterina Mammi, Antonella Montanini, Elisa Barbolini, Monica Bellei, Luigi Marcheselli, Giovanni Partesotti, Alessia Bari, Antonio Maiorana, Tullio Artusi, Massimo Federico

Blood (2006) 108 (11): 4628.

https://doi.org/10.1182/blood.V108.11.4628.4628

Published: 2006

Journal Articles

Early Response to a Short Course of Induction Chemotherapy Overcomes the Prognostic Role of IPI in Patients with Aggressive NHL. Preliminary Results of the GISL LA05 Trial.

Nicola Di Renzo, MD, Stefano Luminari, MD, Antonella Montanini, BSc,PhD, Mario Petrini, MD, Maura Brugiatelli, MD, Paolo G. Gobbi, MD, Caterina Stelitano, MD, Francesco Angrilli, MD, Maurizio Musso, MD, Luca Baldini, MD, Patrizio Mazza, MD, Elsa Pennese, MD, Massimo Federico, MD

Blood (2006) 108 (11): 2434.

https://doi.org/10.1182/blood.V108.11.2434.2434

Published: 2006

NARROW

Baseline Characteristics from Arise Study, an Italian Non-Interventional Study Assessing the Real-World Use of Acalabrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Survival after First Relapse in Marginal Zone Lymphomas: Prospective Data from the International Observational NF10 Study By the Fondazione Italiana Linfomi

Baseline Characteristics from CLL-ZANU2024, an Italian Non-Interventional Study Assessing the Real-World Use of Zanubrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Survival Patterns of Non-Randomized Patients in the IELSG37 Study: Deauville Score 4 Is Not Necessarily Associated with Poor Outcome in Primary Mediastinal Lymphoma

A Snapshot of the Management of Chronic Lymphocytic Leukemia in Italy. Preliminary Analysis on over 3000 Patients Enrolled in the Gimema CLL2121 Trial

Real-World Outcome of Treatment with Single-Agent Ibrutinib in Patients with Chronic Lymphocytic Leukemia: Results from the Italian Study Evidence

Obinutuzumab-Based Immunochemotherapy Mitigates Early Progression Risk with a Substantial 2-Year Progression-Free Survival (PFS) in Patients with Previously Untreated Advanced Follicular Lymphoma and a FLIPI Score ≥2: An Interim Analysis of the Ambispective Urban Study

Comparison between R-COMP and R-CHOP in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Substudy of the Elderly Project By the Fondazione Italiana Linfomi

The Use of Ibrutinib in Italian CLL Patients Treated in a Real-World Setting (EVIDENCE): A Preliminary Report

Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs

Pre-Existing and Treatment-Emergent Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Drugs

Clinical Relevance of Individual Response to Iron Chelation Therapy (ICT) in Patients with Myelodysplastic Syndromes (MDS) and Transfusion Requirement

Definition and Validation of the New Elderly Prognostic Index (EPI) for Elderly Patients with Diffuse Large B-Cell Lymphoma Integrating Geriatric and Clinical Assessment: Results of the Prospective "Elderly Project" on 1353 Patients By the Fondazione Italiana Linfomi

Unmanipulated, G-CSF-Primed Bone Marrow Transplantation From Haploidentical Donor for Patients with High-Risk Acute Myeloid Leukemia.

Cyclophosphamide, Vincristine, Myocet and Prednisone ± Rituximab (COMP±R) Regimen Is Safe and Effective as First Line or Salvage Therapy in Elderly Non Hodgkin Lymphoma (NHL): Preliminary Data of Single Centre Experience.

Efficacy and Safety of Yttrium-90 Ibritumomab Tiuxetan in Older Patients with Indolent Non-Hodgkin Lymphoma.

Velcade, Thalidomide and Dexamethasone (VTD) Regimen Followed by High-Dose Chemotherapy Plus Autologous Stem Cell Transplant (HDT-ASCT) as Front-Line treatment in Newly Diagnosed Multiple Myeloma (MM) Patients: Preliminary Results of An ongoing Open Label Study

Incidence, Clinical Characteristics and Survival of Malignant Lymphomas in the Province of Modena (Italy); a Population-Based Study.

Early Response to a Short Course of Induction Chemotherapy Overcomes the Prognostic Role of IPI in Patients with Aggressive NHL. Preliminary Results of the GISL LA05 Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only